Upstream Bio (UPB) Change in Receivables (2023 - 2026)
Upstream Bio's (UPB) quarterly Change in Receivables came in at $366000.0 in Q1 2026, up 878.72% year-on-year from $37395.7 in Q1 2025, and up 2540.0% quarter-over-quarter from -$15000.0 in Q4 2025.
Upstream Bio (UPB) Change in Receivables (2023 - 2026) Analysis & Trends
Upstream Bio's Change in Receivables history runs 4 years deep, the most recent figure standing at $366000.0 for Q1 2026.
- On a quarterly basis, Change in Receivables rose 878.72% year-over-year to $366000.0 in Q1 2026; TTM through Mar 2026 was $468000.0, a 372.09% increase from a year earlier, with the FY2025 full-year figure at $55000.0, down 89.32% from the prior year.
- Change in Receivables climbed to $366000.0 in Q1 2026 per UPB's latest filing, from -$15000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $640000.0 in Q1 2024 and bottomed at -$254000.0 in Q3 2025.
- The 4-year median for Change in Receivables is -$4500.0 (2024), against an average of $76900.0.
- Across the five-year window, Change in Receivables plunged 361.86% in 2025 and surged 878.72% in 2026, its largest moves.
- Year by year, Change in Receivables stood at -$167000.0 in 2023, then jumped by 103.59% to $6000.0 in 2024, then tumbled by 350.0% to -$15000.0 in 2025, then jumped by 2540.0% to $366000.0 in 2026.
- Per Business Quant, the three latest UPB Change in Receivables figures stand at $366000.0 (Q1 2026), -$15000.0 (Q4 2025), and -$254000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 75.30 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Upstream Bio | 343.65 Mn | 343.65 Mn | -3.94 Mn | 366,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 366,000.00 |
| Mar 31, 2026 | 366,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Sep 30, 2025 | -254,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Jun 30, 2025 | 371,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Mar 31, 2025 | -47,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Sep 30, 2024 | 97,000.00 |
| Jun 30, 2024 | -228,000.00 |
| Jun 30, 2024 | -228,000.00 |
| Mar 31, 2024 | 640,000.00 |
| Mar 31, 2024 | 640,000.00 |
| Dec 31, 2023 | -167,000.00 |
| Dec 31, 2023 | -167,000.00 |